Interferon Treatment Improves Survival among Liver Transplant Recipients with Recurrent Hepatitis C
Journal Title: Journal of Surgery - Year 2013, Vol 1, Issue 1
Abstract
Hepatitis C in the liver allograft recipient has an aggressive course. A significant proportion of such recipients develop graft fibrosis and cirrhosis within five years of transplantation. Treatment efficacy with standard or pegylated interferon and ribavirin is suboptimal compared to the immunocompetent individuals. However, the effect of such therapy on graft and patient survival remains unknown. Objectives: To determine the efficacy of interferon based therapies in liver transplantation recipients with recurrent hepatitis C, and to determine the effect of interferon treatment on graft and patient survival. Methods: We retrospectively analyzed 823 hepatitis C patients, who underwent liver transplantation at Thomas E Starzl Transplantation Institute, University of Pittsburgh between January 1992 and April 2006. Two hundred and sixty four patients received either interferon (all kinds) monotherapy, or combination therapy. The primary end point was graft failure and death. Results: Both treated and untreated groups were similar in clinical characteristics at the time of transplantation. In treatment group, 77% received prednisone based immunosuppression as compared to 75% in no treatment group. 57% of patients in treatment group had HCV RNA >1 million units/ml after transplantation. Patients were categorized into four groups; no treatment (n=440), ≤ 24 weeks of treatment (n=38), 25-48 weeks of treatment (n=64) and >48 weeks of treatment (162). Total bilirubin > 2 at 6 and 12 months and an AST/ALT ratio of >1 at 6 month of transplantation are independently associated with poor patient survival. Patients who received treatment for >48 weeks have significantly improved survival independent of sustained viral response (HR 0.33, p=< 0.001). Conclusion: Among liver transplant recipients with recurrent hepatitis C, treatment with any interferon with or without ribavirin for >48 weeks is significantly associated with improved patient survival regardless of viral response. Prospective trials are indicated to confirm these findings.
Authors and Affiliations
Shahid Habib
Keywords
Related Articles
- EP ID EP203756
- DOI 10.13188/2332-4139.1000007
- Views 119
- Downloads 0
Delayed Cardiac Injury from Gradual Bullet Fragment Erosion into the Right Ventricle
Penetrating cardiac injuries are among the most lethal of all traumatic injuries, with many studies citing mortalities of 70-90% [1-3]. Such injuries account for a very small proportion of annual trauma admissions (0.1%)...
Biopsies of the Internal Mammary Sentinel Lymph Nodes in Breast Cancer
Background: The aim of the present study was to report internal mammary sentinel lymph node (IM SLN) biopsy results and to review and discuss their impact on treatment and prognosis. Patients and methods: We retrospecti...
Comparison of J-Shaped Incision and Mercedes Incision for Liver Transplantation
Wound-related and incision-related complications such as wound infections and incisional hernias are common after liver transplantation. Advances in surgical, anesthesiological, critical care, and immunological innovatio...
Phytotherapy for Benign Prostatic Hyperplasia: The Clinical Efficay and Safety of Use of Prostacare in Patients with Mild to Moderate Lower Urinary Tract Symptoms
Background: Benign prostatic Hyperplasia (BPH) is the commonest benign tumour affecting men worldwide often causing structural or functional obstruction of the bladder neck with manifestation of lower urinary tract sympt...
Umbilical Pilonidal Disease;Predisposing Factors & Best Modality of Management
Umbilical pilonidal sinus is an unusual variant of the pilonidal diseases. It occurs with an incidence thought to be 0.6%. Little was reported in literature about the disease. This study is a prospective one that aims at...